PPARG and hypertrophy: However, when selective PPARγ agonist rosiglitazone (RSG) was used for treating diabetes, it had adverse cardiovascular effects, such as stimulating cardiac hypertrophy and oxidative stress that are independent of cardiomyocyte PPARγ.